Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background.
Saved in:
| Title: | Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. |
|---|---|
| Authors: | Robinson, J.G.1, Farnier, M.2, Kastelein, J.J.3, Roth, E.M.4, Taskinen, M.R.5, Colhoun, H.M.6, Brunet, A.7, DiCioccio, A.T.8, Lecorps, G.9, Pordy, R.10, Baccara-Dinet, M.T.11, Cannon, C.P.12 |
| Source: | Atherosclerosis (00219150). Sep2016, Vol. 252, pe231-e231. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 118311225 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Robinson%2C+J%2EG%2E%22">Robinson, J.G.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Farnier%2C+M%2E%22">Farnier, M.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Kastelein%2C+J%2EJ%2E%22">Kastelein, J.J.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Roth%2C+E%2EM%2E%22">Roth, E.M.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Taskinen%2C+M%2ER%2E%22">Taskinen, M.R.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Colhoun%2C+H%2EM%2E%22">Colhoun, H.M.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Brunet%2C+A%2E%22">Brunet, A.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22DiCioccio%2C+A%2ET%2E%22">DiCioccio, A.T.</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Lecorps%2C+G%2E%22">Lecorps, G.</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Pordy%2C+R%2E%22">Pordy, R.</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Baccara-Dinet%2C+M%2ET%2E%22">Baccara-Dinet, M.T.</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Cannon%2C+C%2EP%2E%22">Cannon, C.P.</searchLink><relatesTo>12</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Atherosclerosis+%2800219150%29%22">Atherosclerosis (00219150)</searchLink>. Sep2016, Vol. 252, pe231-e231. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=118311225 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.atherosclerosis.2016.07.219 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: e231 Titles: – TitleFull: Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Robinson, J.G. – PersonEntity: Name: NameFull: Farnier, M. – PersonEntity: Name: NameFull: Kastelein, J.J. – PersonEntity: Name: NameFull: Roth, E.M. – PersonEntity: Name: NameFull: Taskinen, M.R. – PersonEntity: Name: NameFull: Colhoun, H.M. – PersonEntity: Name: NameFull: Brunet, A. – PersonEntity: Name: NameFull: DiCioccio, A.T. – PersonEntity: Name: NameFull: Lecorps, G. – PersonEntity: Name: NameFull: Pordy, R. – PersonEntity: Name: NameFull: Baccara-Dinet, M.T. – PersonEntity: Name: NameFull: Cannon, C.P. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: Sep2016 Type: published Y: 2016 Identifiers: – Type: issn-print Value: 00219150 Numbering: – Type: volume Value: 252 Titles: – TitleFull: Atherosclerosis (00219150) Type: main |
| ResultId | 1 |
